Teresa Przytycka

Has grant

senior investigator

National Institutes of Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Combinatorial and graph theoretical approach to systems biology and mol. evo.

Open Date:

Close Date:

Articles (8)

Year:

2026

Mutational signatures are characteristic patterns of mutation frequencies assumed to be generated by specific mutagenic processes. A growing catalog of mutational signatures exists, but tools to systematically infer relationships between them remain limited. A mutational signature can be viewed as the combined outcome of two processes: DNA damage and DNA repair. Since cancer therapies often target DNA repair, inferring DNA repair pathways is important for treatment design, even when the mutagenic process is unknown. Here, we model the DNA repair step as a transformation, called RePrint, from damaged nucleotides to repair-related mutation patterns conditioned on the damage. We demonstrate that RePrint similarity is indicative of shared DNA repair mechanisms, enabling guilt-by-association prediction of DNA repair pathways. Using experimentally annotated signatures from environmental exposures and CRISPR gene knockouts as gold standards, we demonstrate that RePrint-based clustering consistently outperforms signature-based clustering across multiple evaluation metrics. We validate several guilt-by-association predictions with literature evidence, demonstrating RePrint’s ability to identify shared repair mechanisms even among signatures with divergent mutational profiles. RePrint provides the first approach to systematically transfer DNA repair information between signatures, opening doors to understanding signatures of unknown origin and informing therapeutic strategies. An open-source implementation is available at https://github.com/wojtowicz-lab/RePrintPy

Year:

2026

Spatially resolved transcriptomics (SRT) technology has enabled a new level of knowledge about tumors. Many critical tumor properties, such as invasiveness and growth, depend on both specific transcriptomic changes in tumor cells and the tumor microenvironment. However, computational methods to study clinical phenotypes of spatial regions, such as hazard and drug response, have not yet been developed. Since clinical phenotypes are measured at the patient level and not at the level of spatial regions, such a method would require transferring knowledge from the patient level domain to the spot level domain. To overcome this challenge, we developed SpacePhenotyper. Our approach uses algebraic spectral techniques to transfer the predictive relationship between gene expression and clinical phenotypes from bulk gene expression data to SRT data. Our approach captures a gene expression pattern that is predictive of the phenotype of interest in the form of a vector, the “Eigen-Patient,” which is then used to quantify the phenotype in spatial spots. After extensively validating SpacePhenotyper on simulated and real data, we utilize it to study how the spatial heterogeneity of breast cancer tumors influences residual cancer burden after treatment. By assigning relative quantities of clinical phenotypes to spatial locations, SpacePhenotyper has proven a powerful tool for the identification and interpretation of transcriptional changes over spatial regions and of spatially-regulated patterns of cellular states. SpacePhenotyper is implemented in Python. The source code and data sets used for and generated during this study are available at https://github.com/ncbi/SpacePhenotyper

Year:

2025

Species and sex-specific differences in organ size are fundamental features of animal biology, yet the mechanisms that drive these differences remain debated. Adult female Drosophila are larger than males. While most organs are present across both sexes, the underlying mechanisms driving sex-specific organ and body size scaling of Drosophila remain unclear. Using single-nucleus transcriptomes from the Fly Cell Atlas, combined with experimental validation, we show that different Drosophila organs scale through distinct strategies, including cell size, cell number, or a combination of both, in an allometric rather than uniform manner. Larger female flight muscles develop from more myoblasts than in males, while cardiomyocyte numbers are the same despite forming a larger heart in females. Female fat body cells are larger and express more ribosomal protein-coding mRNAs, supporting increased cell size. In contrast, males have a greater number of fat body cells. Together, this sex-specific allometry in cell size and number define the cellular basis for differences in body and organ size between sexes in Drosophila . By uncovering how a conserved developmental system produces sex-specific proportions through distinct cellular strategies, our work offers a framework for dissecting sex differences in other species and systems.

Year:

2025

Most solid tumors harbor somatic mutations attributed to off-target activities of APOBEC3A (A3A) and/or APOBEC3B (A3B). However, how APOBEC3A/B enzymes affect tumor evolution in the presence of exogenous mutagenic processes is largely unknown. Here, multi-omics profiling of 309 lung cancers from smokers identifies two subtypes defined by low ( LAS ) and high ( HAS ) APOBEC mutagenesis. LAS are enriched for A3B-like mutagenesis and KRAS mutations; HAS for A3A-like mutagenesis and TP53 mutations. Compared to LAS, HAS have older age at onset and high proportions of newly generated progenitor-like cells likely due to the combined tobacco smoking- and APOBEC3A-associated DNA damage and apoptosis. Consistently, HAS exhibit high expression of pulmonary healing signaling pathway, stemness markers, distal cell-of-origin, more neoantigens, slower clonal expansion, but no smoking-associated genomic/epigenomic changes. With validation in 184 lung tumor samples, these findings show how heterogeneity in mutational burden across co-occurring mutational processes and cell types contributes to tumor development.

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Collaborators (15)

David Levens

Senior investigator

National Institutes of Health

UNITED STATES
View details

Dmitry Gordenin

Principal Investigator

National Institute of Environmental Health Sciences

UNITED STATES
View details

angela pesatori

Full Professor in Occupational Medicine

University of Milan

ITALY
View details

Reuben S. Harris

Professor

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Stephen Chanock

National Institutes of Health

UNITED STATES
View details

Soumitra Pal

Staff Scientist

National Eye Institute

UNITED STATES
View details

Georg Vogler

Research Assistant Professor

Sanford Burnham Prebys Medical Discovery Institute

UNITED STATES
View details

Roded Sharan

Academic, Full Professor, Full Professor

Tel Aviv University

ISRAEL
View details

Elizabeth J. Rideout

Associate Professor

The University of British Columbia

CANADA
View details

Ludmil Alexandrov

Professor

University of California, San Diego

UNITED STATES
View details

David Wedge

The University of Manchester

UNITED KINGDOM
View details

Damian Wójtowicz

Assistant Profesor

University of Warsaw

POLAND
View details

Frank Schnorrer

CNRS Délégation Côte d'Azur

FRANCE
View details

Robert Homer

Yale University School of Medicine

UNITED STATES
View details

Chi-Ping Day

Staff Scientist

National Cancer Institute

UNITED STATES
View details